Barclays PLC Raises Holdings in Inari Medical, Inc. (NASDAQ:NARI)

Barclays PLC grew its holdings in shares of Inari Medical, Inc. (NASDAQ:NARI - Free Report) by 9.7% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 288,079 shares of the company's stock after buying an additional 25,365 shares during the quarter. Barclays PLC owned 0.49% of Inari Medical worth $11,881,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Nisa Investment Advisors LLC boosted its holdings in Inari Medical by 83.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 956 shares of the company's stock valued at $46,000 after acquiring an additional 435 shares during the period. GAMMA Investing LLC lifted its position in shares of Inari Medical by 67.2% during the third quarter. GAMMA Investing LLC now owns 1,177 shares of the company's stock worth $49,000 after purchasing an additional 473 shares during the last quarter. KBC Group NV boosted its stake in shares of Inari Medical by 39.0% during the third quarter. KBC Group NV now owns 1,774 shares of the company's stock valued at $73,000 after purchasing an additional 498 shares during the period. Benjamin F. Edwards & Company Inc. grew its holdings in shares of Inari Medical by 39.4% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company's stock worth $89,000 after purchasing an additional 522 shares during the last quarter. Finally, Covestor Ltd grew its holdings in shares of Inari Medical by 63.5% in the third quarter. Covestor Ltd now owns 2,384 shares of the company's stock worth $99,000 after purchasing an additional 926 shares during the last quarter. Institutional investors own 90.98% of the company's stock.

Insider Buying and Selling

In related news, Director William Hoffman sold 60,000 shares of the business's stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $51.16, for a total transaction of $3,069,600.00. Following the completion of the transaction, the director now owns 501,233 shares in the company, valued at $25,643,080.28. The trade was a 10.69 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Andrew Hykes sold 3,000 shares of the firm's stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $50.00, for a total transaction of $150,000.00. Following the completion of the sale, the chief executive officer now owns 445,310 shares of the company's stock, valued at approximately $22,265,500. This trade represents a 0.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 143,000 shares of company stock worth $7,022,400 in the last three months. 10.60% of the stock is owned by insiders.

Inari Medical Price Performance

NASDAQ NARI traded up $1.16 during midday trading on Monday, hitting $56.75. 1,036,748 shares of the company traded hands, compared to its average volume of 989,258. Inari Medical, Inc. has a 52 week low of $36.73 and a 52 week high of $67.10. The company's 50-day simple moving average is $48.70 and its 200-day simple moving average is $47.95. The company has a market cap of $3.32 billion, a PE ratio of -41.18 and a beta of 0.97.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Robert W. Baird boosted their price objective on shares of Inari Medical from $66.00 to $67.00 and gave the company an "outperform" rating in a research report on Tuesday, October 29th. Leerink Partners began coverage on shares of Inari Medical in a research note on Tuesday, September 3rd. They set a "market perform" rating and a $47.00 price target for the company. Needham & Company LLC reissued a "hold" rating on shares of Inari Medical in a research note on Tuesday, October 29th. Truist Financial raised their price objective on Inari Medical from $46.00 to $50.00 and gave the stock a "hold" rating in a report on Tuesday, October 29th. Finally, Piper Sandler upped their target price on Inari Medical from $50.00 to $52.00 and gave the stock a "neutral" rating in a report on Tuesday, October 29th. Six research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, Inari Medical has an average rating of "Hold" and an average target price of $58.89.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.